The CATALYST Initiative:
Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies:
A Focus on CLL
Questions marked with a
Based on results from interphase cytogenetic analysis by fluorescence in situ hybridization (FISH), which chromosomal abnormality has been linked to the poorest overall survival rate for patients with chronic lymphocytic leukemia (CLL)?
Based on current treatment guidance, which of the following front-line therapeutic options would you discuss with your 70-year-old patient with CLL who has comorbidities?
Bendamustine + rituximab, acalabrutinib, ibrutinib, or venetoclax + obinutuzumab
Fludarabine + cyclophosphamide + rituximab (FCR), acalabrutinib + rituximab, ibrutinib, or venetoclax + rituximab
Ibrutinib, acalabrutinib + rituximab, FCR, or venetoclax + rituximab
Obinutuzumab +/– chlorambucil, acalabrutinib + obinutuzumab, ibrutinib, or venetoclax + obinutuzumab
Based on the CLL10 study, when comparing fludarabine + cyclophosphamide + rituximab (FCR) versus bendamustine + rituximab, the risk of severe neutropenia was:
Lower in the FCR group (35% vs 76%)
Higher in the FCR group (84% vs 59%)
Similar between the two groups (49% vs 51%)
Continue Without Answering